CD86 and neoplasm: Furthermore, base on the intraperitoneal xenograft model, we not only discovered that the TSA monotherapy demonstrated the fewest metastatic foci relative to the other treatment groups (FigureS2A,B, Supporting Information), but also identified the higher CD86 expression of macrophage cells in TSA monotherapy group (FigureS2C–E, Supporting Information), indicating that the therapeutic efficacy of TSA may be linked to alterations in the tumor microenvironment.